Page last updated: 2024-08-22

vidarabine and Angioimmunoblastic Lymphadenopathy

vidarabine has been researched along with Angioimmunoblastic Lymphadenopathy in 6 studies

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (33.33)	18.2507
2000's	3 (50.00)	29.6817
2010's	1 (16.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chadwick, H; Counsell, N; Evans, K; Johnson, RJ; Pottinger, BT; Rudin, CE; Smith, P; Townsend, W; Wickham, C	1
Bourikas, G; Kaloutsi, V; Margaritis, D; Pantelidou, D; Spanudakis, E; Tsatalas, C	1
Koeppen, H; Larson, RA; Olopade, OI; Ong, ST	1
Hast, R; Hjalmar, V; Jacobsson, B; Petrescu, A	1
Auxenfants, E; Bourgeois, E; Dubest, C; Jouffrey, C; Mahieu, M; Rose, C	1
Bourikas, G; Kaloutsi, V; Kotsianidis, I; Margaritis, D; Martinis, G; Tsatalas, C	1

Trials

1 trial(s) available for vidarabine and Angioimmunoblastic Lymphadenopathy

Article	Year
A phase II clinical trial of fludarabine and cyclophosphamide followed by thalidomide for angioimmunoblastic T-cell lymphoma. An NCRI clinical trial. CRUK number C17050/A5320. Leukemia & lymphoma, 2016, Volume: 57, Issue:9 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Drug Administration Schedule; Female; Humans; Immunoblastic Lymphadenopathy; Lymphoma, T-Cell; Male; Middle Aged; Survival Analysis; Thalidomide; Vidarabine	2016

Article

Year

A phase II clinical trial of fludarabine and cyclophosphamide followed by thalidomide for angioimmunoblastic T-cell lymphoma. An NCRI clinical trial. CRUK number C17050/A5320.

Leukemia & lymphoma, 2016, Volume: 57, Issue:9

Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Drug Administration Schedule; Female; Humans; Immunoblastic Lymphadenopathy; Lymphoma, T-Cell; Male; Middle Aged; Survival Analysis; Thalidomide; Vidarabine

2016

Other Studies

5 other study(ies) available for vidarabine and Angioimmunoblastic Lymphadenopathy

Article	Year
Treatment of angioimmunoblastic lymphadenopathy with dysproteinemia-type T-cell lymphoma with fludarabine. Acta haematologica, 2003, Volume: 109, Issue:2 Topics: Antineoplastic Agents; Female; Humans; Hypergammaglobulinemia; Immunoblastic Lymphadenopathy; Lymphoma, T-Cell; Middle Aged; Remission Induction; Vidarabine	2003
Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia with fludarabine. Blood, 1996, Sep-15, Volume: 88, Issue:6 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Immunoblastic Lymphadenopathy; Male; Middle Aged; Prednisone; Vidarabine; Vincristine	1996
Successful treatment with fludarabine in two cases of angioimmunoblastic lymphadenopathy with dysproteinemia. Leukemia & lymphoma, 1999, Volume: 34, Issue:5-6 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Immunoblastic Lymphadenopathy; Lymphoma, T-Cell; Middle Aged; Remission Induction; Vidarabine	1999
[Efficacy of fludarabine in the treatment of angioimmunoblastic lymphoma (AIL)]. Annales de medecine interne, 2000, Volume: 151, Issue:3 Topics: Humans; Immunoblastic Lymphadenopathy; Immunosuppressive Agents; Male; Middle Aged; Remission Induction; Vidarabine	2000
Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia-type T-cell lymphoma with fludarabine. Acta haematologica, 2001, Volume: 105, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Schedule; Humans; Immunoblastic Lymphadenopathy; Lymphoma, T-Cell; Male; Middle Aged; Treatment Outcome; Vidarabine	2001